Documents to download

The regulations for medicines and medical devices in the UK are currently set at a European level. All medicines must be authorised by either the European Medicines Agency (EMA) or the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) on the basis of EU standards. In practice, the two bodies work together to assess medicines before authorisation and to monitor them afterwards. Medical devices must also conform to EU standards.

Medicine regulation in the UK will be affected by its departure from the EU. Under the draft withdrawal agreement, during the transition period, cooperation between the MHRA and the EMA will continue, and following the transition period, the political declaration stated that the UK and EU would “explore the possibility of cooperation”. If the UK leaves with no deal, all products authorised at the European level would automatically be authorised in the UK, and the MHRA will take on the functions of the EMA for the UK.

Ongoing developments in medicine safety include the role of technology, for example in analysing multiple databases on patient and drug experiences. Others include new methods of introducing drugs, new processes for clinical trials and enhanced education and training on safety regulation.

In February 2018, following incidents of side effects from three products, the Government launched the Independent Medicines and Medical Devices Safety Review to recommend improvements to the response to patient reports about harmful side effects. The review has so far taken evidence from a variety of sources, but has not announced a date for the publication of its main findings.

Finally, medicine safety can be seen in the context of wider patient safety initiatives. Several government and non-governmental bodies are working in this area, most prominently NHS Improvement, which is developing a new patient safety strategy.


Documents to download

Related posts

  • US tariffs: Background, perspectives and impact on the UK

    The US has announced significant increases in tariffs on imports, although has delayed full implementation. Many economists view tariffs unfavourably, arguing that they raise prices, reduce competition and risk retaliation. But others suggest that tariffs may benefit the country that applies them. UK exports to the US face an additional 10% tariff. This could be negative for UK exports and the economy. But there could be some upsides for the UK if the US goes ahead with higher “reciprocal” tariffs on many of the UK’s competitors.

    US tariffs: Background, perspectives and impact on the UK
  • Tobacco and Vapes Bill: HL Bill 89 of 2024–25

    The bill aims to create a 'smoke-free generation' by banning tobacco sales to anyone born on or after 1 January 2009, alongside other measures to tackle smoking and tobacco harms. It would also further regulate vaping, curbing its appeal to children, while enabling adult smokers to use vapes as a quitting tool. The bill is similar to the Tobacco and Vapes Bill which fell at dissolution 2024.

    Tobacco and Vapes Bill: HL Bill 89 of 2024–25
  • Science and Technology Committee report on seizing the opportunity of engineering biology

    Engineering biology involves designing and building new biological systems, molecules, or organisms. It has potential applications ranging from medicines and manufacturing to making new materials or more resilient crops. The House of Lords Science and Technology Committee has urged the government to seize the opportunities presented by this technology and warned that without urgent action the UK risks losing the potential benefits of remaining a world-leader in the field.

    Science and Technology Committee report on seizing the opportunity of engineering biology